Childhood cancer receives 4% of U.S. federal funding for cancer research and only 1% of this goes to DIPG. Lola is the first patient to qualify for Phase I of the clinical trial at St. Jude. The goal is to find if the child can withstand the side effects under the highest possible dose. December 16, 2016.